Shenduo Li, MD, PhD

Thoracic Medical Oncology@MayoClinic FL

[Shenduo Li, MD, PhD @ShenduoLi]

I can see one problem in future daraxonrasib trial design: I doubt any patient would want to be in the control arm.

[NEJM @NEJM]

Presented at #ASCO26:

Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: https://t.co/xwLWBZYRzq

@ASCO

[Shenduo Li, MD, PhD @ShenduoLi]

@LukasDelasos @CleClinicMD @Maedezkn @n8pennell @jamecancerdoc Congrats man! Tried to say hello today but you were so popularly surrounded by people :)

[Shenduo Li, MD, PhD @ShenduoLi]

Our incoming chief fellow Dr. Tanmayi Pai is moderating a work life balance discussion for all trainees and early career faculty 👏👏👏 #ASCO24 @ASCO @MayoClinic @MayoCancerCare

[Shenduo Li, MD, PhD @ShenduoLi]

@MayoCancerCare

[Shenduo Li, MD, PhD @ShenduoLi]

Our very best program director Dr. @RManochakian is moderating a very hot topic of managing locally advanced NSCLC! 👏👏👏 #ASCO24 @ASCO @MayoClinic

[Shenduo Li, MD, PhD @ShenduoLi]

@OsamaMosalemMD @OncLive @drjasonstarr @RManochakian @AdamKase @DrWinstonTan1 @guicorreiamd Congratulations!!🎊🎉

[Shenduo Li, MD, PhD @ShenduoLi]

@guicorreiamd @OncLive @RManochakian @DrYanyanLou Congratulations!! 🎉

[Shenduo Li, MD, PhD @ShenduoLi]

@RManochakian @ASCO @MayoClinic @MayoCancerCare Congratulations Dr. Manochakian! So happy for you! 👏👏👏🎉🎊🎉

[Shenduo Li, MD, PhD @ShenduoLi]

My take are: promising phase 2 result, at least comparable. Need phase 3 data to stand out from this already competitive PD1/PDL1 inhibitor arena.

[Shenduo Li, MD, PhD @ShenduoLi]

Great presentation and discussion of PERLA trial by Drs. Peters and Reguart. Exciting numerical OS advantage of dostarlimab+CT over pembrolizumab+CT 19.4 v 15.9m. However, was pembro+CT underperforming comparing to KN189, especially in PD-L1>50% subgroup? @myESMO #ESMO23

[Shenduo Li, MD, PhD @ShenduoLi]

@RManochakian @JAMAOnc Thank you Dr. Manochakian! Appreciate your mentorship!

[Rami Manochakian MD, FASCO Cancer Education @RManochakian]

@JAMAOnc 3/3
Very proud of 1st author Dr. Li @ShenduoLi (outstanding #HemOnc fellow and future thoracic oncologist).

[Rami Manochakian MD, FASCO Cancer Education @RManochakian]

🔥🚨@OncoAlert Just out @JTOonline by our team @MayoCancerCare:

#CaseReport on a sequential #SmallCell transformation & #ALK I1171T mutation as resistance mechanisms in a pt with #ALK-EML4 #NSCLC treated with combination of #Temozolomide & #Lorlatinib

👇🏼
https://t.co/GkixRkDWr5

[Mayo Clinic Comprehensive Cancer Center @MayoCancerCare]

At #ASCO23 Dr. @RManochakian, thoracic oncologist & vice chair for education at @MayoClinic in Florida, presented in an education session on integrating #LearningScience principles and how to "ACE" teaching through oncology presentations to make them memorable and effective.

[Rami Manochakian MD, FASCO Cancer Education @RManochakian]

🔥🚨@OncoAlert #ASCO23 NEGATIVE results of #Keynote789 trial:

Platinum + Pem +/- Pembro for TKI-resistant #EGFR mutant #NSCLC

❌PFS HR 0.8, P=0.0122
mPFS: 5.6 vs 5.5 mths

❌OS HR 0.84, P=0.0362
mOS: 15.9 vs 14.7 mths

After TKI , adding Pembro to chemo DOES NOT improve OS

[Lei Deng, MD (He/Him) @LeiDeng3]

#ASCO23 🫁WU-KONG6: Phase 2 Sunvozertinib for EGFR Exon20Ins
1⃣ORR 60.8% (48.5% in pts w/ brain mets)
2⃣ORR consistent across loop location
3⃣Median DOR not reached after median f/u at 7.1 mos for responders
✅A new promising drug for EGFR Exon20Ins

[Shenduo Li, MD, PhD @ShenduoLi]

Great work by @LovaSunMD @CharuAggarwalMD published during #ASCO23 . Answered a clinical-relevant question that many practicing oncologists are waiting for. Congrats!

[JAMA Oncology @JAMAOnc]

Study of patients with #NSCLC showed no survival difference between 2-yr fixed duration vs indefinite #immunotherapy, suggesting that IO can be d/c at 2 yrs.

@PennCancer @flatironhealth @lovasunMD @Ron_cology @CharuAggarwalMD #ASCO23

https://t.co/EWyneghc8a

[Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ @APassaroMD]

🆕in @CCR_AACR an analysis investigating the efficacy of Osi in pts with lung cancer harbouring *uncommon* EGFR exon 19 del mut’s

E746_A750del was associated with significantly prolonged mPFS with 1L Osi vs. L747_A750>P (21.3 vs. 11.7m; [HR] 0.52 ; p=0.043).

Understanding differences in Osi efficacy among EGFR ex19del subtypes could alter management of these pts in the future

https://t.co/OOhZBLEck4

[Shenduo Li, MD, PhD @ShenduoLi]

Fresh and hot updates at #ELCC23 on CM816, showing persistent benefits of neoadjuvant Nivo+chemo in resectable NSCLC. Interestingly, the benefits seem more in preventing distal metastasis rather than local recurrence. What could be a possible explanation?@nicogirardcurie @myESMO

[Shenduo Li, MD, PhD @ShenduoLi]

@tnewsomdavis @myESMO @IASLC Most audiences cannot wait to see the Papillon trial results lol

[Shenduo Li, MD, PhD @ShenduoLi]

Although it’s cold and rainy in Copenhagen, feeling the heat in #ELCC23 lung cancer conference. A big discrepancy in audiences in choosing 1st line therapy for EGFR ex20ins LUAD. Speaker Dr Girard chose chemo+bev to avoid immunotherapy. @myESMO @IASLC